Portfolio Detail Shoreline Biome

Venture Portfolio

Shoreline Biome

CEO:
Mark Driscoll

About:
Shoreline Biome’s next-generation sequencing (NGS) test provides the first rapid and cost-effective method for looking at the microbiome at sufficient resolution to use as a diagnostic test. C. difficile and other related microbiome imbalances are currently identified separately using individual tests, sometimes multiple tests, for each possible pathogen. Other NGS systems lack the read length needed to classify organisms to the species/strain level needed for diagnostic tests. The test identifies pathogenic changes from multiple microbial sources that could adversely affect hospitalized individuals.

CI Representative:
Patrick O’Neill
Director, Investments

back to portfolio